The U.S. reprocessed medical devices market size was exhibited at USD 1.80 billion in 2023 and is projected to hit around USD 8.29 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2024 to 2033.
Reprocessing medical devices contribute to a more sustainable healthcare system by reducing waste and conserving resources. It helps to minimize the environmental impact associated with manufacturing, packaging, and disposing of new medical devices. In addition, reprocessed medical devices are often more affordable than their new counterparts, making them an attractive option for healthcare facilities and patients seeking to reduce expenses.
Report Coverage | Details |
Market Size in 2024 | USD 2.10 Billion |
Market Size by 2033 | USD 8.29 Billion |
Growth Rate From 2024 to 2033 | CAGR of 16.5% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product Type, Type, End-use |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Country scope | U.S. |
Key Companies Profiled | Stryker; Innovative Health; NEScientific, Inc.; Medline Industries, Inc; Arjo; Vanguard AG; Cardinal Health; SureTek Medical; Soma Tech Intl; Johnson & Johnson Services, Inc. |
Governments and regulatory bodies in the U.S. are recognizing the value of reprocessed medical devices and are implementing policies and guidelines to support their use. For instance, according to the Association of Medical Device Reprocessors (AMDR), hospitals in the U.S. could save around USD 2.28 billion annually by maximizing their use of reprocessed single-use medical devices. According to the same source, in 2020, the U.S. hospitals saved approximately USD 372 million by reprocessing single-use medical devices, as reprocessed devices costed 25% to 40% less than manufacturing new devices.
In addition, certain factors including the increasing prevalence of cardiovascular disorders, enhancement in the healthcare infrastructure, and increasing proportion of aging population, are anticipated to contribute to the market growth. According to the information published by the Population Reference Bureau in January 2024, the 65 and older population in the U.S. is expected to increase to 82 million in 2050 from 58 million in 2022. The increasing proportion of this population is expected to drive demand for reprocessed medical devices owing to their higher susceptibility to diseases.
Reprocessing of medical equipment provides a solution that reduces medical waste, decreases greenhouse gas emissions, and encourages a safer, cleaner, and more environmentally friendly healthcare system. The rising prevalence of chronic diseases fuels the market demand for reprocessed medical devices utilized in various surgical procedures. The adoption of these devices enables healthcare facilities to achieve cost savings without compromising patient care or safety.
The cardiovascular segment dominated the market and accounted for a share of 56.51% in 2023 and is expected to register the fastest CAGR during the forecast period. Cardiovascular diseases, such as heart disease, strokes, and hypertension, are among the leading cardiovascular diseases and disability worldwide. According to the Centers for Disease Control and Prevention, in May 2023, heart disease is one of the major causes of death in the U.S. It is estimated that one person dies every 33 seconds in the country from cardiovascular diseases. Moreover, about 695,000 people in the U.S. died from heart disease in 2021-that's 1 in every five deaths. This high prevalence leads to a significant demand for medical devices used in cardiovascular treatments and diagnostics, which, in turn, creates demand for reprocessed medical devices.
Hospitals and healthcare facilities can benefit from using reprocessed cardiovascular devices, as they can be up to 60-90% less expensive than new, single-use devices. The cardiovascular segment encompasses a diverse array of medical devices, such as catheters, pacemakers, defibrillators, and monitoring equipment. This variety allows for a more significant impact on the reprocessed medical devices market, as multiple types of devices can be reprocessed and reused, catering to different cardiovascular procedures and treatments.
The hospitals segment dominated the market share of 40.0% in 2023 and is expected to register the fastest CAGR during the forecast period. Hospitals and healthcare facilities face increasing financial pressures due to rising costs of healthcare services and equipment. Reprocessed medical devices offer significant cost savings compared to purchasing new, single-use devices. This cost-effectiveness makes reprocessed devices more appealing to hospitals, as it helps them manage their budgets more efficiently. Moreover, the healthcare industry generates a large amount of waste, including medical devices and equipment. Reprocessing medical devices helps reduce the environmental impact of healthcare facilities by minimizing the amount of waste generated from single-use devices.
In some cases, there may be shortages of specific medical devices due to supply chain disruptions, manufacturing issues, or high demand. Reprocessed devices can help bridge these gaps by providing an alternative source of medical equipment that is still safe and effective for use. Regulatory authorities such as FDA also work to ensure safety of these devices by reviewing premarket and postmarket information from manufacturers to reduce the risk of hospital acquired infections through these devices.
3rd party reprocessing accounted for the largest market revenue share in 2023 and is expected to register the fastest CAGR during the forecast period. Third-party reprocessing companies often offer cost-effective solutions for reprocessing medical devices. These companies consolidate reprocessing activities in specialized facilities to achieve economies of scale, which in turn leads to lower prices for reprocessed devices compared to purchasing new, single-use devices. Third-party reprocessors often have established processes and protocols for reprocessing various types of medical devices. This standardization helps ensure consistency in the quality of reprocessed devices across different manufacturers and models.
The preference for third-party reprocessing in the reprocessed medical devices market stems from the cost savings, quality assurance, standardization, and reduced burden on healthcare facilities that these companies provide. This allows healthcare providers to access high-quality, reprocessed medical devices at a lower cost, ultimately benefiting both patients and healthcare institutions. For instance, according to the information published by Stryker, in 2023, their sustainability solutions helped customers shift around 5 million pounds of waste through reprocessing programs and saved them around 3,250 customers, approximately USD 238 million.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. reprocessed medical devices market
Product Type
Type
End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product type
1.2.2. Type
1.2.3. End-use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product type outlook
2.2.2. Type outlook
2.2.3. End-use outlook
2.3. Competitive Insights
Chapter 3. U.S. Reprocessed Medical Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of diseases
3.2.1.2. Technological advancements in healthcare
3.2.1.3. Increasing emphasize on costs cutting
3.2.2. Market restraint analysis
3.2.2.1. Stringent regulations & approvals
3.3. U.S. Reprocessed Medical Devices Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Reprocessed Medical Devices Market: Product Type Estimates & Trend Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. U.S. Reprocessed Medical Devices Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
4.4.1. Cardiovascular
4.4.1.1. Market estimates and forecasts 2021 to 2033
4.4.1.2. Blood pressure cuffs
4.4.1.2.1. Market estimates and forecasts 2021 to 2033
4.4.1.3. Positioning devices
4.4.1.3.1. Market estimates and forecasts 2021 to 2033
4.4.1.4. Cardiac stabilization devices
4.4.1.4.1. Market estimates and forecasts 2021 to 2033
4.4.1.5. Diagnostic electrophysiology catheters
4.4.1.5.1. Market estimates and forecasts 2021 to 2033
4.4.1.6. Deep vein thrombosis compression sleeves
4.4.1.6.1. Market estimates and forecasts 2021 to 2033
4.4.1.7. Electrophysiology cables
4.4.1.7.1. Market estimates and forecasts 2021 to 2033
4.4.2. Laparoscopic
4.4.2.1. Market estimates and forecasts 2021 to 2033
4.4.2.2. Harmonic scalpels
4.4.2.2.1. Market estimates and forecasts 2021 to 2033
4.4.2.3. Endoscopic trocars
4.4.2.3.1. Market estimates and forecasts 2021 to 2033
4.4.3. Gastroenterology
4.4.3.1. Market estimates and forecasts 2021 to 2033
4.4.3.2. Biopsy forceps
4.4.3.2.1. Market estimates and forecasts 2021 to 2033
4.4.3.3. Others
4.4.3.3.1. Market estimates and forecasts 2021 to 2033
4.4.4. General surgery
4.4.4.1. Market estimates and forecasts 2021 to 2033
4.4.4.2. Pressure bags
4.4.4.2.1. Market estimates and forecasts 2021 to 2033
4.4.4.3. Balloon inflation devices
4.4.4.3.1. Market estimates and forecasts 2021 to 2033
4.4.5. Orthopedic
4.4.5.1. Market estimates and forecasts 2021 to 2033
Chapter 5. U.S. Reprocessed Medical Devices Market: Type Estimates & Trend Analysis
5.1. Type Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. U.S. Reprocessed Medical Devices Market by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
5.4.1. 3rd party reprocessing
5.4.1.1. Market estimates and forecasts 2021 to 2033
5.4.2. In-house reprocessing
5.4.2.1. Market estimates and forecasts 2021 to 2033
Chapter 6. U.S. Reprocessed Medical Devices Market: End-use Estimates & Trend Analysis
6.1. End-use Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. U.S. Reprocessed Medical Devices Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the Following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2021 to 2033
6.4.2. Home healthcare
6.4.2.1. Market estimates and forecasts 2021 to 2033
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2021 to 2033
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. Stryker
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Innovative Health
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. NEScientific, Inc.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Medline Industries, Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Arjo
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Vanguard AG
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Cardinal Health
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. SureTek Medical
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Soma Tech Medical
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Johnson & Johnson Services, Inc.
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives